@drmichaelsays

1 post audited · 6 claims analysed

Instagram profile

Science evidence grade

92%High evidence grade

Based on 6 claims across 1 audit

SupportedOverstatedMisleadingNo Evidence

5

Supported

83%

1

Overstated

17%

0

Misleading

0%

0

No Evidence

0%

Share this evidence grade

Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards

What @drmichaelsays claims actually are

We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).

Evidence-based

83%

5 claims

Claims that align with published human or clinical evidence at the stated strength.

Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.

Factually incorrect

0%

0 claims

Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.

Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.

Grey / overstated

17%

1 claim

Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.

Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.

Evidence mix

Share of audited claims in each bucket

Loading…
BackedIncorrectGrey

Verdict detail

Grey splits into overstated (wrong certainty) vs no published support

Loading…

Claims over time

Stacked by bucket as audits land — plus the running evidence grade

Loading…

Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).

Audit history(1 post)

Post thumbnail
Supported
Posted Apr 26, 2026·3 months ago·View post

Doctor Ranks ALL Peptides: The Truth About What Actually Works

Five of six claims are directly supported by scientific literature or regulatory fact (Melanotan II mechanism, side effects, AOD 9604's weak human evidence, PT-141 FDA approval, and IGF-1 oncology risk). One claim (Melanotan II → melanoma causation) is overstated—the connection is theoretically plausible but not empirically proven in humans. Across all claims, the creator has presented accurate mechanistic concepts and regulatory facts, though notably without explicit citations; where internal PeptIQ references exist (PT-141 FDA approval, Ipamorelin selectivity), they confirm the creator's statements. The overall body of claims reflects an honest, evidence-aligned assessment of peptide pharmacology and regulatory status.

Audit another post from @drmichaelsays

Paste their social post link to add a new audit

New audit